COHBAR INC (CWBR)

US19249J3077 - Common Stock

0.761  -0.14 (-15.44%)

After market: 0.7345 -0.03 (-3.48%)

Fundamental Rating

2

CWBR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. While CWBR seems to be doing ok healthwise, there are quite some concerns on its profitability. CWBR does not seem to be growing, but still is valued expensively.



0

1. Profitability

1.1 Basic Checks

CWBR had negative earnings in the past year.
CWBR had a negative operating cash flow in the past year.
In the past 5 years CWBR always reported negative net income.
In the past 5 years CWBR always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of CWBR (-101.44%) is worse than 79.57% of its industry peers.
The Return On Equity of CWBR (-133.58%) is worse than 64.45% of its industry peers.
Industry RankSector Rank
ROA -101.44%
ROE -133.58%
ROIC N/A
ROA(3y)-68.44%
ROA(5y)-73.98%
ROE(3y)-75.95%
ROE(5y)-95.1%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

CWBR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, CWBR has more shares outstanding
CWBR has more shares outstanding than it did 5 years ago.
CWBR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

CWBR has an Altman-Z score of -13.68. This is a bad value and indicates that CWBR is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CWBR (-13.68) is worse than 84.22% of its industry peers.
There is no outstanding debt for CWBR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -13.68
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

CWBR has a Current Ratio of 4.16. This indicates that CWBR is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 4.16, CWBR perfoms like the industry average, outperforming 42.36% of the companies in the same industry.
CWBR has a Quick Ratio of 4.16. This indicates that CWBR is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of CWBR (4.16) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.16
Quick Ratio 4.16

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 8.02% over the past year.
EPS 1Y (TTM)8.02%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-58.51%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-3.7%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

CWBR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CWBR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for CWBR!.
Industry RankSector Rank
Dividend Yield N/A

COHBAR INC

NASDAQ:CWBR (11/28/2023, 7:00:00 PM)

After market: 0.7345 -0.03 (-3.48%)

0.761

-0.14 (-15.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.21M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -101.44%
ROE -133.58%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 4.16
Quick Ratio 4.16
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)8.02%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-3.7%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y